Protein tyrosine phosphatase delta is a STAT3-phosphatase and suppressor of metabolic liver disease.

OBJECTIVE

Impaired hepatic expression of protein tyrosine phosphatase delta () is associated with increased STAT3 transcriptional activity and reduced survival from hepatocellular carcinoma in patients with chronic hepatitis C virus infection. However, the -expressing hepatic cell types, signalling pathways responsive to PTPRD and their role in non-viral liver disease are largely unknown.

METHODS

We studied expression in single-cell and bulk liver transcriptomic data from mice and humans, and established a -deficient mouse model for metabolic dysfunction-associated steatohepatitis (MASH). Identified pathways were validated by perturbation studies in human hepatocytes and PTPRD substrates by pull-down assays. The clinical relevance was further explored in a cohort with metabolic disease by ranking patients according to expression and analysing its association with metabolic disease markers.

RESULTS

The analysis of individuals ranked according to expression and -deficient mice, showed that levels were associated with hepatic glucose/lipid signalling and peroxisome function. Hepatic expression is impaired in aetiologies of chronic liver diseases that are associated with metabolic disease. We further validated PTPRD as a STAT3 phosphatase in the liver, acting as a regulator of peroxisomal fatty acid metabolism. During MASH, low PTPRD led to increased liver steatosis in +/- mice and a pronounced unfolded protein response, which impacts insulin signalling. Accordingly, silencing of blunted insulin-induced AKT phosphorylation. Patients with obesity and low hepatic expression exhibit increased levels of metabolic risk factors.

CONCLUSION

Our data revealed an important regulatory role of the hepatic PTPRD-STAT3 axis in maintaining glucose/lipid homeostasis, which is recapitulated in clinical manifestations of metabolic liver disease.